Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials-Reference-Cited by-同舟云学术

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

Published:2018-08 Issue:10148 Volume:392 Page:650-661
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Gordon Kenneth B,Strober Bruce,Lebwohl Mark,Augustin Matthias,Blauvelt Andrew,Poulin Yves,Papp Kim A,Sofen Howard,Puig Lluís,Foley Peter,Ohtsuki Mamitaro,Flack Mary,Geng Ziqian,Gu Yihua,Valdes Joaquin M,Thompson Elizabeth H Z,Bachelez Hervé

Publisher

Elsevier BV

Subject

General Medicine

Reference29 articles.

1. Psoriasis;Di Meglio;Cold Spring Harb Perspect Med,2014

2. Psoriasis;Boehncke;Lancet,2015

3. The global burden of psoriatic skin disease;Goff;Br J Dermatol,2015

4. Global epidemiology of psoriasis: a systematic review of incidence and prevalence;Parisi;J Invest Dermatol,2013

5. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey;Lebwohl;J Am Acad Dermatol,2014

Cited by 494 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The immunologic role of IL-23 in psoriatic arthritis: a potential therapeutic target;Expert Opinion on Biological Therapy;2024-09-08

2. Real-World Effectiveness and Safety of Risankizumab in Adult Patients with Plaque Psoriasis: A 16-Week International Multicenter Retrospective Cohort Study;Journal of Cutaneous Medicine and Surgery;2024-09-03

3. Clinical efficacy of risankizumab in patients with psoriasis: A Japanese case series;JAAD International;2024-09

4. Quality of reporting and concordance between sources of adverse events in the treatment of moderate-to-severe psoriasis: a cross-sectional study of RCTs from a Cochrane systematic review;Journal of Clinical Epidemiology;2024-09

5. Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 Substudy;JID Innovations;2024-09